Clinical trials: Enoxaparin
Small Cell Lung Cancer
A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer
The endpoint is to investigate if the addition of low molecular heparin - enoxaparin, will result in a significant increase of overall survival in patients with small cell lung cancer, receiving standard chemotherapy.
- Trial name
- RASTEN (NCT00717938)
- Testing
- cisplatinum or carboplatin and e.g.etoposide., cisplatinum or carboplatin and e.g.etoposide+enoxaparin
- Where
- 16 sites in Sweden
- Volunteers
- 390 people
- Sponsor
- Lund University Hospital
Severe Acute Respiratory Syndrome, Ventilation Pneumonitis
Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19
The associated use of Ivermectin, aspirin, dexamethasone, and enoxaparin (in different combinations and doses) will reduce the impact of COVID infection 19, the need of admission to the intensive care unit, and mortality.
- Trial name
- IDEA (NCT04425863)
- Testing
- Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets, Ivermectin 5 mg/mL oral solution, Dexamethasone 4-mg injection, Aspirin 250 mg tablets, Ivermectin 5 MG/ML oral solution, Dexamethasone 4-mg injection, Enoxaparin injection. Inpatient treatment with mechanical ventilation in ICU.
- Where
- Argentina
- Volunteers
- 167 people
- Sponsor
- Eurnekian Public Hospital
Blood Clot, Trauma
PREVENTion of Clot in Orthopaedic Trauma
The purpose of this study is to compare aspirin versus low-molecular weight heparin (LMWH) (Enoxaparin) as a thromboprophylaxis in patients who sustain a fracture.
- Trial name
- PREVENT CLOT (NCT02984384)
- Testing
- Acetylsalicylic acid, Low Molecular Weight Heparin (LMWH)
- Where
- 21 sites in United States, Canada
- Volunteers
- 12,424 people
- Sponsor
- Major Extremity Trauma Research Consortium
COVID-19
Lung Injury (Pulmonary Edema) in COVID-19: Treatment With Furosemide and Negative Fluid Balance (NEGBAL)
In COVID-19, pulmonary edema has been attributed to "cytokine storm". However, it is known that SARS-CoV-2 promotes angiotensin-converting enzyme 2 deficiency, it increases angiotensin II and this triggers volume overload.
- Trial name
- NCT05304702
- Where
- Argentina
- Volunteers
- 120 people
- Sponsor
- Clinica Colon
Arthritis, Osteoarthritis, Knee
Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement
The study will describe the short-term effects the study drug, rivaroxaban, has on the body when a patient is switched from enoxaparin injection (by needle) to oral rivaroxaban (by mouth) for the prevention of blood clotting in…
- Conditions
- Arthritis, Osteoarthritis, Knee, Osteoarthritis, Hip, Thromboembolism
- Trial name
- NCT01094886
- Testing
- Rivaroxaban
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Covid19
Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection
The COVID-19 infection primarily manifests itself as a respiratory tract infection, although new evidence indicates that this disease has systemic involvement involving multiple systems including the cardiovascular, respiratory…
- Trial name
- HEPMAB (NCT04600141)
- Testing
- Tocilizumab, Heparin - Therapeutic dosage, Heparin - Prophylactic dosage
- Where
- 3 sites in Brazil
- Volunteers
- 308 people
- Sponsor
- University of Sao Paulo
Bleeding
A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa
This is a randomized, double-blind, study in healthy volunteers dosed to steady state with fXa inhibitors, designed to (1) demonstrate PK/PD comparability between andexanet manufactured by the Generation 1 and Generation 2…
- Trial name
- NCT03083704
- Testing
- Andexanet alfa (Gen 1 Process 2), Apixaban 5 MG, Rivaroxaban 20 MG
- Where
- United States
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Portola Pharmaceuticals
Deep Vein Thrombosis, Venous Thrombosis
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis
Assess the relative change in thrombus volume as determined by two assessments (Baseline and Day 14-21) with magnetic resonance venography (MRV) in subjects with deep-vein thrombosis (DVT) treated with either an edoxaban…
- Trial name
- eTRIS (NCT01662908)
- Testing
- edoxaban tosylate, enoxaparin/unfractionated heparin, warfarin
- Where
- 34 sites in United States, Canada
- Volunteers
- 85 people
- Sponsor
- Daiichi Sankyo
Acute Myocardial Infarction
The STREAM Percutaneous Coronary Intervention Anticoagulant Sub-study
The purpose of this study is to assess the safety and efficacy of Enoxaparin and Unfractionated Heparin in St Elevation Myocardial Infarction patients undergoing primary percutaneous coronary intervention.
- Trial name
- NCT00882635
- Testing
- enoxaparin, Unfractionated heparin
- Where
- 2 sites in Canada
- Volunteers
- 44 people
- Sponsor
- Robert Welsh
Venous Thromboembolism
An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study
The study drug, BAY59-7939, is a new drug currently being tested in the prevention of VTE. It directly inhibits factor Xa, a blood component in the pathway which leads to coagulation (clotting of blood cells).
- Trial name
- NCT00402467
- Testing
- Rivaroxaban (BAY59-7939), Rivaroxaban, (BAY59-7939), Enoxaparine
- Where
- 36 sites in United States, Canada
- Volunteers
- 613 people
- Sponsor
- Bayer
Acute Coronary Syndrome
Tirofiban and Enoxaparin in High Risk Coronary Intervention
Patients undergoing coronary angioplasty are frequently treated with new drugs that stop blood platelets working and so improve the success of the procedure. Individual patients may vary in the dose of the drug required.
- Trial name
- NCT00790387
- Testing
- Enoxaparin, Tirofiban, unfractionated heparin
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- The Prince Charles Hospital
Placental Insufficiency, Enoxaparin
Enoxaparin in the Prevention of Placental Insufficiency in Pregnant Women
Assessment of the effectiveness of Enoxaparin, at a preventive dose, combined with Aspirin treatment versus Aspirin only treatment in reducing placental insufficiency in pregnant women.
- Trial name
- PRESANCE (NCT03528967)
- Testing
- Enoxaparin 40 mg / 0.4 mL Prefilled Syringe, Aspirin 100 mg Oral Tablet, Enteric Coated
- Where
- Tunisia
- Volunteers
- 89 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Stroke of Basilar Artery, Optical Coherence Tomography
Optical Coherence Tomography Guided Antithrombotic Treatment After Endovascular Thrombectomy of the Posterior Circulation
Evidence regarding the role of early (<24 hours) antithrombotics post-revascularization with either intravenous thrombolysis (IVT), endovascular thrombectomy (EVT), or a combination of both remains scarce.
- Conditions
- Stroke of Basilar Artery, Optical Coherence Tomography, Antithrombotics, Endovascular Thrombectomy
- Trial name
- NCT04121611
- Testing
- Unfractionated heparin, Acetylsalicylic Acid (ASA)
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Sunnybrook Health Sciences Centre
Unstable Angina
Ischemia Driven Enoxaparin Therapy in ACS Presenting as Low Risk (IDEAL)
The purpose of this study is to determine whether enoxaparin (an anticoagulant) is effective in the treatment of patients presenting to the emergency room with chest pain and no electrocardiogram or bloodwork evidence of a heart…
- Trial name
- IDEAL (NCT00518245)
- Testing
- enoxaparin
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- Canadian Heart Research Centre
Intrauterine Growth Restriction
Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction
The local literature lacks comprehensive information regarding the actual incidence of intrauterine growth restriction (IUGR) and oligohydramnios and currently available therapeutic options.
- Trial name
- NCT07462182
- Testing
- Enoxaparin, Standard Management
- Where
- Pakistan
- Volunteers
- 108 people
- Sponsor
- Muhammad Aamir Latif
COVID-19 Acute Respiratory Distress Syndrome, Hypoxemia
Effects of Low Molecular Weight Heparin Therapy With Soft-Mist Inhaler for COVID-19 Induced Hypoxemia
This is an investigator initiated, single-center, open-label, Phase IIb clinical trial with 40 patients (for a total of 80 patients) to assess efficacy of Low molecular weight heparin using soft mist inhaler in the treatment of…
- Trial name
- NCT04990830
- Testing
- Inhaled Low molecular weight heparin, Standard Treatment
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Istanbul University
Systemic Lupus Erythematosus, Pregnancy Related
Treatment and Clinical Outcomes Among SLE Patients in Pregnancy
Systemic lupus erythematosus (SLE) is a kind of systemic autoimmune disease which can cause multiple organs and system damage, which often occurs in women of childbearing age.
- Trial name
- NCT04976465
- Testing
- Anticoagulation, Without Anticoagulation
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Qilu Hospital of Shandong University
Hand Surgery
The Safety of Hand Surgery in the Anticoagulated Patient
If operating on the anticoagulated patient has been safe for one of the investigators' surgeons for the past 10 years then providing prospective data that substantiates this could prevent complications related to the…
- Trial name
- NCT00954928
- Where
- United States
- Volunteers
- 398 people
- Sponsor
- Washington University School of Medicine
Skin Burn Extensive
Evaluation Of Enoxaparin Pharmacokinetic For Thromboprophylaxis In Burn Care Patients
OVERVIEW: Thromboembolisms represent a serious and feared complication in hospitalized patients. Several factors make the ICU patient population at increased risk of venous thromboembolism.
- Trial name
- NCT01421537
- Where
- Canada
- Volunteers
- 180 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Venous Thromboembolism
Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement
The main purpose of this study is to determine if an investigational medication called SelK2 works in preventing a condition called "venous thromboembolism" (VTE) in patients having a total knee replacement.
- Trial name
- COURSE (NCT03812328)
- Testing
- SelK2, Enoxaparin
- Where
- 21 sites in Bulgaria, Latvia and 3 more
- Volunteers
- 207 people
- Sponsor
- Tetherex Pharmaceuticals Corporation